EA202091201A1 - COMPOSITIONS IN THE FORM OF INJECTED AQUEOUS SOLUTION CONTAINING AMILINE, AMILINE RECEPTOR AGONIST OR AMILINE ANALOGUE AND COPOLYAMINO ACID - Google Patents

COMPOSITIONS IN THE FORM OF INJECTED AQUEOUS SOLUTION CONTAINING AMILINE, AMILINE RECEPTOR AGONIST OR AMILINE ANALOGUE AND COPOLYAMINO ACID

Info

Publication number
EA202091201A1
EA202091201A1 EA202091201A EA202091201A EA202091201A1 EA 202091201 A1 EA202091201 A1 EA 202091201A1 EA 202091201 A EA202091201 A EA 202091201A EA 202091201 A EA202091201 A EA 202091201A EA 202091201 A1 EA202091201 A1 EA 202091201A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amiline
aqueous solution
receptor agonist
copolyamino acid
analogue
Prior art date
Application number
EA202091201A
Other languages
Russian (ru)
Inventor
Ю-Пин Чань
Александр Жессле
Ромен Ноэль
Ришар Шарве
Никола Лоран
Original Assignee
Адосья
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адосья filed Critical Адосья
Priority claimed from PCT/EP2018/083943 external-priority patent/WO2019110788A1/en
Publication of EA202091201A1 publication Critical patent/EA202091201A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Изобретение относится к композиции в форме водного раствора для инъекций, для которой рН составляет от 6,0 до 8,0, включающей, по меньшей мере, a) амилин, агонист рецептора амилина или аналог амилина; b) сополиаминокислоту, несущую карбоксилатные заряды и гидрофобные радикалы Hy, причем указанная сополиаминокислота состоит из глутаминовых или аспарагиновых звеньев и указанные гидрофобные радикалы Hy выбраны в соответствии с формулой X, как определено нижеотличающейся тем, что композиция не содержит базального инсулина, для которого изоэлектрическая точка IP составляет от 5,8 до 8,5. Это также относится к композиции, отличающейся тем, что она также содержит прандиальный инсулин.The invention relates to a composition in the form of an aqueous solution for injection, for which the pH is from 6.0 to 8.0, comprising at least a) amylin, amylin receptor agonist or analog of amylin; b) a copolyamino acid bearing carboxylate charges and Hy hydrophobic radicals, wherein said copolyamino acid consists of glutamic or aspartic units and said hydrophobic Hy radicals are selected according to formula X, as defined below, characterized in that the composition does not contain basal insulin, for which the isoelectric point IP ranges from 5.8 to 8.5. This also applies to a composition characterized in that it also contains prandial insulin.

EA202091201A 2018-06-29 2018-12-07 COMPOSITIONS IN THE FORM OF INJECTED AQUEOUS SOLUTION CONTAINING AMILINE, AMILINE RECEPTOR AGONIST OR AMILINE ANALOGUE AND COPOLYAMINO ACID EA202091201A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1855943A FR3083085B1 (en) 2018-06-29 2018-06-29 COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
PCT/EP2018/083943 WO2019110788A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid

Publications (1)

Publication Number Publication Date
EA202091201A1 true EA202091201A1 (en) 2020-09-29

Family

ID=65031316

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091201A EA202091201A1 (en) 2018-06-29 2018-12-07 COMPOSITIONS IN THE FORM OF INJECTED AQUEOUS SOLUTION CONTAINING AMILINE, AMILINE RECEPTOR AGONIST OR AMILINE ANALOGUE AND COPOLYAMINO ACID

Country Status (2)

Country Link
EA (1) EA202091201A1 (en)
FR (1) FR3083085B1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (en) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
EP0717635B1 (en) 1993-09-07 2000-11-15 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
FR2855521B1 (en) * 2003-05-28 2005-08-05 Flamel Tech Sa POLYAMINOACIDES FUNCTIONALIZED BY AT LEAST ONE YDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS.
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
US9173991B2 (en) 2007-07-02 2015-11-03 Roche Diabetes Care, Inc. Device for drug delivery
EA027744B1 (en) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Formulations for the treatment of diabetes mellitus
BR112014016889A8 (en) * 2012-01-09 2017-07-04 Adocia composition in the form of an aqueous injectable solution ph is comprised between 6.0 and 8.0 and unit dose formulation with ph comprised between 7 and 7.8

Also Published As

Publication number Publication date
FR3083085A1 (en) 2020-01-03
FR3083085B1 (en) 2020-10-02

Similar Documents

Publication Publication Date Title
EA201892736A1 (en) INLETE UNIQUE PAGE
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
SG11201810901VA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
EA201791419A1 (en) SUPERFORCEDIZED POLYMER MODIFIED BY ISOCIANATIC LINKER AND A MIXTURE OF SIMPLE SHORT AND LONG-SECONDARY ALKYL POLYESTERS
BR112017022349A2 (en) "compound, composition, method, and method for inhibiting an irak protein"
PH12020550827A1 (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
EA201892123A1 (en) 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDIN-5-CARBOXAMIDE AS APJ AGONISTS
MA38289A1 (en) Pharmaceutical composition with improved bioavailability
EA201890584A1 (en) NEW INSULIN ANALOGUES AND THEIR APPLICATION
MX2020005914A (en) Injectable solution with a ph of 7 comprising at least one basal insulin with a pi of between 5.8 and 8.5 and a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals.
PH12021550464A1 (en) Isoxazoline compounds for controlling invertebrate pests
GEP20207139B (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
EA202092464A1 (en) METHODS FOR PREPARING STABLE PROTEIN-BASED COMPOSITIONS
PE20230108A1 (en) VARIANTS OF CANINE ANTIBODIES
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
EA201991023A1 (en) PHARMACEUTICAL COMPOSITION FOR Parenteral Administration Containing Karglum Acid
ECSP21003130A (en) ISOXAZOLINE COMPOUNDS TO CONTROL INVERTEBRATE PESTS
BR112019026577A8 (en) AMINOTHIAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS
EA202091201A1 (en) COMPOSITIONS IN THE FORM OF INJECTED AQUEOUS SOLUTION CONTAINING AMILINE, AMILINE RECEPTOR AGONIST OR AMILINE ANALOGUE AND COPOLYAMINO ACID
MX2021001671A (en) Protein bar.
MX2015002279A (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.
AR105764A1 (en) FORMULATION OF HIGHLY CONCENTRATED THIOPHOSPHORIC OR PHOSPHORIC TRIAMIDE
EA202091387A1 (en) COMPOSITIONS IN THE FORM OF INJECTED AQUEOUS SOLUTION CONTAINING HUMAN GLUCAGON AND COPOLYAMINO ACID
FR3061023B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR3074682B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID